Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aimmune Therap (AIMT)

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,173,213
  • Shares Outstanding, K 65,251
  • Annual Sales, $ 0 K
  • Annual Income, $ -248,500 K
  • 60-Month Beta 0.97
  • Price/Sales 1,975.64
  • Price/Cash Flow N/A
  • Price/Book 4.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -1.02
  • Number of Estimates 6
  • High Estimate -0.92
  • Low Estimate -1.19
  • Prior Year -1.01
  • Growth Rate Est. (year over year) -0.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.23 +18.06%
on 05/14/20
18.92 -4.94%
on 06/05/20
+1.27 (+7.60%)
since 05/05/20
3-Month
10.09 +78.20%
on 03/17/20
22.13 -18.75%
on 03/06/20
-4.38 (-19.59%)
since 03/05/20
52-Week
10.09 +78.20%
on 03/17/20
37.00 -51.41%
on 01/16/20
-2.16 (-10.72%)
since 06/05/19

Most Recent Stories

More News
Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive...

AIMT : 17.98 (+0.67%)
New PALFORZIA(TM) Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced it will present important new long-term...

AIMT : 17.98 (+0.67%)
Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers

-- Country-specific data show German respondents experience highest levels of anxiety, more than half of UK respondents report being bullied, and feelings of isolation are most common among French respondents...

AIMT : 17.98 (+0.67%)
After Yesterday's Rally of 2.07% Shares Could Potentially Pullback

Aimmune Therapeu (NASDAQ:AIMT) traded in a range yesterday that spanned from a low of $15.92 to a high of $18.75. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high...

AIMT : 17.98 (+0.67%)
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial...

AIMT : 17.98 (+0.67%)
Aimmune Therapeutics (AIMT) Reports Q1 Loss, Misses Revenue Estimates

Aimmune Therapeutics (AIMT) delivered earnings and revenue surprises of 10.44% and -67.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

AIMT : 17.98 (+0.67%)
Aimmune Therapeutics: 1Q Earnings Snapshot

BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Monday reported a loss of $86.4 million in its first quarter.

AIMT : 17.98 (+0.67%)
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the...

AIMT : 17.98 (+0.67%)
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference...

AIMT : 17.98 (+0.67%)
Global Allergy Immunotherapies Market 2020-2024, Featuring Key Vendor Profiles Including Aimmune Therapeutics, DBV Technologies and Merck KGaA - ResearchAndMarkets.com

The "Global Allergy Immunotherapies Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

AIMT : 17.98 (+0.67%)
MKKGY : 23.7000 (+1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AIMT with:

Business Summary

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and...

See More

Key Turning Points

2nd Resistance Point 19.36
1st Resistance Point 18.67
Last Price 17.98
1st Support Level 17.53
2nd Support Level 17.09

See More

52-Week High 37.00
Fibonacci 61.8% 26.72
Fibonacci 50% 23.55
Fibonacci 38.2% 20.37
Last Price 17.98
52-Week Low 10.09

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar